NCT02135614已完成2 期
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 189
- 试验地点
- 43
- 主要终点
- Time-Weighted Average Change in Respiratory Syncytial Viral (RSV) Load From Baseline to Day 5
研究概览
简要总结
The primary objective of this study is to evaluate the effects of presatovir on respiratory syncytial virus (RSV) viral load in RSV-positive adults who have been hospitalized with acute respiratory infectious symptoms.
Participants will receive 1 dose of presatovir on Day 1 and followed for 27 days postdose. Nasal swabs will be collected at each study visit (excluding Day 28) and assayed for change in viral load as the primary endpoint.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Current inpatient
- •New onset of acute respiratory infectious symptoms, or acute worsening of chronic symptoms related to ongoing respiratory disease for ≤ 5 days prior to screening:
- •Upper respiratory tract symptoms: nasal congestion, runny nose, sore throat, or earache
- •Lower respiratory tract symptoms: cough, sputum production, wheezing, dyspnea, or chest tightness
- •Documented to be RSV-positive at the current admission within 72 hours of screening, or as evaluated at screening
排除标准
- •Related to concomitant or previous medication use:
- •Use of oral prednisone or other corticosteroid equivalent to:
- •> 20 mg/day for > 14 days prior to screening is not permitted.
- •> 20 mg/day for ≤ 14 days, including corticosteroids received during current hospitalization (ie, bolus doses), is permitted.
- •≤ 20 mg/day, regardless of duration, is permitted.
- •Individuals taking a moderate or strong cytochrome P450 enzyme (CYP) inducer including but not limited to rifampin, St John's Wort, carbamazepine, phenytoin, efavirenz, bosentan, etracirine, modafinil, and nafcillin within 2 weeks prior to the first dose of study drug
- •Related to medical history:
- •Pregnant, breastfeeding, or lactating females
- •Individuals requiring > 50% supplemental oxygen (while the individual is awake) at screening
- •Individuals with a Clinical Frailty Scale (CFS) > 7 at Baseline
- •Known significant abnormality altering the anatomy of the nose or nasopharynx that in, the opinion of the investigator, will preclude obtaining adequate nasal swab sampling in either nasal passage
- •Waiting for or recently (within the past 12 months) received a bone marrow, stem cell, or solid organ transplant, or who have received radiation or chemotherapy within 12 months prior to Screening
- •Individuals with HIV/AIDS and a known CD4 count < 200 cells/uL
- •History of severe dementia or Alzheimer's disease
- •History of drug and/or alcohol abuse that, in the opinion of the investigator, may prevent adherence to study activities
- •Related to medical condition at screening:
- •Influenza-positive as determined by local diagnostic test
- •Known Middle East Respiratory Syndrome coronavirus (MERS-CoV) infection or known coinfection with other coronavirus
- •Use of mechanical ventilation during the current admission, not including noninvasive ventilation
- •Clinically significant bacteremia or fungemia that has not been adequately treated prior to Screening, as determined by the investigator
- •Inadequate treatment of confirmed bacterial, fungal, or non-RSV pneumonia, as determined by the investigator
- •Excessive nausea/vomiting at admission, as determined by the investigator, that precludes administration of an orally administered study drug
- •Related to allergies:
- •Known allergy to components of the study drug (microcrystalline cellulose, mannitol, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol and talc)
- •Documented history of acute (anaphylaxis) or delayed (Stevens-Johnson syndrome or epidermal necrolysis) allergy to sulfa drugs
- •Note: Other protocol defined Inclusion/Exclusion criteria may apply.
研究组 & 干预措施
Presatovir
Experimental
Participants will receive a single dose of presatovir.
干预措施: Presatovir (Drug)
Presatovir placebo
Placebo Comparator
Participants will receive a single dose of presatovir placebo.
干预措施: Presatovir placebo (Drug)
结局指标
主要结局
Time-Weighted Average Change in Respiratory Syncytial Viral (RSV) Load From Baseline to Day 5
时间窗: Baseline to Day 5
The time-weighted average change, often referred to as the DAVG, provides the average viral burden change from baseline. The mean values presented were calculated using the ANCOVA model and are adjusted for baseline value and stratification factor.
次要结局
- Time-weighted Average Change in the Flu-PRO Score From Baseline to Day 5(Baseline to Day 5)
- Number of Hospitalization-Free Days Following Presatovir Administration(Up to Day 28)
- Rate of Unplanned Medical Encounters(Up to Day 28)
研究者
研究点 (43)
Loading locations...
相似试验
已完成
2 期
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory TractRespiratory Syncytial VirusNCT02254408Gilead Sciences189
已完成
2 期
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory TractRespiratory Syncytial Virus InfectionNCT02254421Gilead Sciences60
已完成
2 期
Presatovir in Lung Transplant (LT) Recipients With Respiratory Syncytial Virus (RSV) InfectionRespiratory Syncytial Virus (RSV)NCT02534350Gilead Sciences61
终止
1 期
A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and OlderRespiratory Syncytial Virus-associated Lower Respiratory Tract Disease PreventionNCT05327816Janssen Vaccines & Prevention B.V.132
招募中
2 期
RSV Vaccination in Immunocompromised Patients.RSV InfectionNCT06597916Medical University of Vienna200